Search

Cinchocaine

It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) … A local anesthetic of the amide type now generally used for surface anesthesia.

Methoxyphenamine

Emedastine

Emedastine is an antihistamine used in eye drops to treat allergic conjunctivitis.

Tolmetin

A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin.

Pacritinib

[L40793] JAK2 signaling is important for hematopoiesis and proper immune functioning,[L40754] and while the precise role it plays in the pathogenesis of MF remains unclear, its clear association with MF … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment

Clotiazepam

Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.

Lenvatinib

These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as … However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib.

Revumenib

It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … the majority of infant acute lymphoblastic leukemia cases.

Tripelennamine

It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.

Piperaquine

It has come back into use in combination with the artemisinin derivative [DB11638] as part of the combination product Eurartesim [FDA Label]. … Eurartesim was first authorized for market by the European Medicines Agency in October 2011.